BIRMA trial: Is BRAF and MEK inhibition successful in relapsed MM?

During the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, the Multiple Myeloma Hub spoke to Marc S. Raab, Heidelberg University Hospital, Heidelberg, DE, about the BIRMA trial. We asked, Is BRAF and MEK inhibition successful in relapsed multiple myeloma (MM)?

The activating BRAF V600E mutation is a rare mutation that occurs in 4–8% of patients in the refractory setting of MM. In this video, Raab discusses the BIRMA trial, evaluating the combined BRAF and MEK inhibition in patients with heavily pretreated MM with BRAF V600E mutation.